Status:
UNKNOWN
A Phase II Clinical Study of Stereotactic Radiation Therapy in Patients With High-risk Prostate Cancer
Lead Sponsor:
West China Hospital
Conditions:
Prostate Cancer
Stereotactic Body Radiotherapy
Eligibility:
MALE
18-95 years
Phase:
NA
Brief Summary
Stereotactic body radiotherapy (SBRT) has emerged as an effective and safe treatment for low and intermediate-risk prostate cancer(PCa). However, there is no study that has investigated the effectiven...
Eligibility Criteria
Inclusion
- 18 years or older
- pathologically confirmed high-risk (T3a or Gleason score ≥ 8 or a PSA \> 20 ng/ml) prostate cancer
- a WHO performance status 0-1
- history of neoadjuvant androgen deprivation therapy(ADT) within 6 months before enrollment
- Patients with pelvic positive lymph node were also included in our study
Exclusion
- distant metastasis
- history of neoadjuvant ADT over 6 months before enrollment
- history of definitive treatment for prostate cancer such as radical prostatectomy
- history of pelvic irradiation; prostate volume≥100 cm3
Key Trial Info
Start Date :
June 30 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05430737
Start Date
June 30 2022
End Date
June 30 2025
Last Update
June 24 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
China, SiChuan
Chengdu, Sichuan, China, 610041